Navigation Links
Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
Date:12/15/2008

WALTHAM, Mass., Dec. 15 /PRNewswire-FirstCall/ -- On December 10, 2008, Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the American Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on January 15, 2009 to holders of record of Series B stock at the close of business on January 2, 2009.

Such payment will cover the amount of dividends accrued from October 1, 2008 through December 31, 2008.

For more information about Inverness Medical Innovations, please visit our website athttp://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Inverness Medical Innovations to Present at RBC Capital Markets 2008 Healthcare Conference on December 11, 2008
2. Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMPO(TM) Test
3. Inverness Medical Innovations to Present at the Third Annual JMP Securities Healthcare Focus Conference on October 7, 2008
4. Inverness Medical Innovations Announces 4th Generation Rapid HIV Test - Determine(TM) HIV-1/2 Ag/Ab Combo
5. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.
6. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results
7. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
8. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
9. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 20, 2008 to Discuss Fourth Quarter 2007 Results
10. Inverness Medical Innovations to Present at 2008 UBS Global Healthcare Services Conference on February 13, 2008
11. Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research & Road Safety - Queensland (CARRS-Q) study have ... (OSIT) which is being held on the Gold Coast ... road safety researcher, said speed limit credibility was being ... traffic controls remained in place at inactive roadwork sites. ... asked to slow down at roadwork sites but find ...
(Date:9/19/2014)... researchers showed monkeys a number of images representing ... of 39 neurons by using microelectrodes. They found ... intensities of the responses linearly according to either ... This shows that these 3 perceptual parameters are ... variety of glosses. They also found that different ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development firm, has ... Xaverian Brothers. The new site aligns the Catholic order of ... another through a life of Gospel witness lived in community ... care and compassionate love to the people of the world ... responsive web design, which allows users to easily access information ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... Wonder tickets for his 2014 concert tour. Concertgoers ... the music business, there are a handful of artists that ... Wonder. Born in Saginaw, MichIgan, Wonder has been a force ... his time in the music business, he has released 23 ...
(Date:9/19/2014)... September 19, 2014 Lifeinsuranceover50s.biz as released ... who have heart disorders can still qualify for life ... qualify for life insurance plans that do not require ... be purchased online, in just a few minutes. ... also be purchased by clients who have health problems, ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:Neurons express 'gloss' using three perceptual parameters 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... bitten by a bat and subsequently diagnosed with rabies has been ... is being offered, the chances of the boy recovering is very ... of Humble High School fell ill last week, unaware of the ... could happen, a bat had flown into his house while he ...
... study conducted by a team at Queeen's has suggested ... when hooked up to dialysis// yield better results in ... ,This five-month, exercise intervention study of dialysis patients ... King-VanVlack, member of the Cardiac, Circulation and Respiratory (CCR) ...
... that more than 80 million American adults are smokers, obese or ... and an early death. // ,Data from a ... of adults in the United States who have one or both ... categories is about 9 million people and this would include a ...
... study states that the organ donation rate in UK is ... relatives are reluctant to allow such procedures. // This was ... potential organ donors because they are distressed and confused about ... ,The UK Transplant, which carried out a two-year audit, ...
... the Japanese Encephalitis immunization drive has not gone down well ... have taken place on June 18, but the government has ... delivery of 5.2 million doses of the Japanese Encephalitis tissue ... , ,The remaining 13.5 million doses are expected to ...
... to place on record the exemplary work of art by students ... effort by Oman in the ‘Unite for children Unite against Aids’ ... ‘Unite for Children Unite Against Aids’ campaign encompasses four major goals ... the percentage of the young victims of HIV/Aids; to provide better ...
Cached Medicine News:Health News:Exercise Combined with Dialysis Yields Better Results 2Health News:Grieving Relatives Reluctant To Give Consent For Organ Donation 2
(Date:9/19/2014)... 19, 2014 Reductions in kidney ... years in people with diabetes type 2 ... benefits for the kidneys." Australian researchers have ... 2 diabetes leads to persistent reductions in kidney failure ... The global study has found that, five and a ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... , Sept. 18, 2014  Aratana Therapeutics, ... therapeutics company focused on licensing, developing and commercializing ... the full exercise of the underwriters, option to ... connection with the company,s previously announced public offering ... the shares are being offered by Aratana Therapeutics.  ...
Breaking Medicine Technology:ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... Response or Reduction of,Lesion Size by More than ... 2007 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation today announced the ... the safety and,efficacy of pilot process HspE7, an ... women,with the highest grade of cervical dysplasia (CIN ...
... WIRE)--Mar 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel's ... from trials of BL-1040 demonstrating that,BL-1040 is ... a myocardial infarction (MI), thereby reducing left ... pig model. Professor,Jonathan Leor, MD, Director of ...
Cached Medicine Technology:Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
Nitinol Flat Wire Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: